Association between age and infection in patients with acute ST-elevation myocardial infarction

Magdy Algowhary

Abstract

Background: ST-elevation myocardial infarction (STEMI) in young patients has a unique risk profile. We aimed to detect bacteria in aspirate of infarct artery in young versus old patients.

Results: Aspirates of consecutive 140 patients who underwent a primary coronary intervention were taken for bacteriological, microscopical, and immunohistochemical (for bacterial pneumolysin) examinations. Their results were calculated in young (< 50 years) versus old (> 50 years) patients. Median age (interquartile range) was 45 (38–48) years in young (60 patients) and 59 (55–65) years in old (80 patients) patients, \( p < 0.0001 \). Both groups had similar baseline data except age, males, diabetes, hyperlipidemia, family history, lesion length, and ectatic vessel. Different bacteria were cultured in 11.3% of all patients involving 22.6% of young and 2.8% of old patients \([\text{hazard ratio} \ 8.03 \ (95\% \ CI \ 1.83–51.49), \ p = 0.002]\). By multivariate analyses, age groups and leukocytic count were independent predictors of infection (bacteria and pneumolysin), \( p = 0.027 \) and \( p < 0.0001 \), respectively. Optimal cutoff value of leukocytic count was 12,250 cells/\( \mu l \) \([\text{ROC curve sensitivity} \ 85.7\%, \text{specificity} \ 86.4\%, \text{and AUC} \ 0.97 \ (95\% \ CI \ 0.95–1.0), \ p < 0.001]\). Infection was an independent predictor of STEMI in young versus old patients, \( p < 0.001 \). Nevertheless, in-hospital events occurred insignificantly different and neither age groups nor infection was predictor of in-hospital events.

Conclusions: Young patients had significantly higher percentage of bacteria in their infarcted artery than old patients. High leukocytic count in patients below 50 predicts infection that causes acute myocardial infarction. Antibacterial trials directed toward this group are required for secondary prevention.

Keywords: STEMI, Bacteria, Young patients, Primary coronary intervention, Thrombus

Background

Acute myocardial infarction (AMI) holds a substantial footprint on global health affecting more than 7 million individuals worldwide each year causing more than a third of deaths in developed countries annually [1]. The incidence of AMI in young population is universally low and varies according to location. In young Japanese patients, < 40 years, it ranges from 1.6% in AMI-Kyoto Multicenter-Risk Study [2] to less than 5% in Miyagi AMI Registry [3]. The incidence is nearly 4% in Singapore [4], 5.8% in USA (between 25 and 44 years) [5], 1.3% in Poland (< 40 years) in PL-ACS Registry [6], 37.6% in England and Wales (between 18 and < 65 years) in MINAP Registry [7], and 23% in Egypt (< 55 years) [8]. The mortality rate after first AMI attack has declined in all age groups in Denmark [9] and in other developed countries due to improvement in prevention and treatment efforts. However, risk of recurrent hospitalization in young patients is still existing [10] posing a substantial burden on patients and health care resources [11]. Young patients, < 55 years, are at low risk to develop coronary artery disease though they may have traditional risk factors such as dyslipidemia, smoking,
hypertension, diabetes mellitus, chronic kidney disease, male, family history, noncardiogenic cerebral infarction, and peripheral artery disease [12]. Lipid retention and modification is probably the main early trigger for inflammation; however, infection may play a crucial role in atherosclerosis and AMI affecting both old and young patients [13, 14]. This causative relation explains at least in part why infection triggers acute coronary syndromes after pneumococcal pneumonia [15], chlamydia pneumonia [16, 17], and in Helicobacter pylori-seropositive patients having interleukin-1 polymorphisms [18]. Samples obtained from atherosclerotic lesions by catheter-based atherectomy revealed existence of > 50 different species of bacteria [19] and 19 different fungal signatures [20]. Thrombus aspirates of patients with ST-elevation myocardial infarction (STEMI) revealed several oral species and chlamydia pneumoniae [21, 22]. Moreover, samples of epicardial adipose tissue surrounding coronary arteries obtained during bypass grafting from patients with acute coronary syndrome contained bacterial DNA [23] supporting the role of bacteria in the pathogenesis of atherosclerotic plaques and their disruption leading to acute coronary syndrome [24].

In our previous study, consecutive 370 patients with STEMI presented to emergency department between April 2016 and June 2017 who underwent primary coronary intervention were included [25]. STEMI was made when the following criteria were present: (1) typical anginal pain occurring within 24 h, (2) ST-segment elevation in 2 contiguous leads or new left bundle branch block, and (3) positive markers for elevated cardiac enzymes, pneumolysin, and inflammatory cellular infiltration while predictors of STEMI in YP versus OP were identified by using binary logistic regression analysis using forward step-wise method was used to identify predictors of inhospital clinical events and predictors of bacteria, bacterial pneumolysin, and infiltration while predictors of STEMI in YP versus OP were identified by using binary logistic regression analysis using forward step-wise method was used to identify predictors of inhospital clinical events and predictors of bacteria, bacterial pneumolysin, and infiltration while predictors of STEMI in YP versus OP were identified by using binary logistic regression analysis using forward step-wise method was used to identify predictors of inhospital clinical events and predictors of bacteria, bacterial pneumolysin, and infiltration while predictors of STEMI in YP versus OP were identified by using binary

**Methods**

**Population and laboratory studies**

A total of 140 aspirates were taken from 370 consecutive STEMI patients. Bacteriological, microscopical, and histopathological examinations were performed simultaneously depending on the size of thrombus aspirates. If the sample was enough, it was put into two sterile containers. The first container had sterile 2 ml of saline and was used for bacterial culture on different bacterial media, and the results were confirmed by VITEK 2 system (in 124 patients). The rest of the sample was embedded in formalin 10% inside the second container and was stained by hematoxylin and eosin for microscopical examination to detect inflammatory cells, polymorphonuclear leukocytes, and lymphocytes (in 79 patients). Histopathologic study was performed by withdrawing 2 ml of blood from the infarct-related artery to detect bacterial pneumolysin by using ELISA test (in 60 patients). Of note, each step was accomplished under strict sterile techniques to avoid bacterial contamination [25].

In this study, the results of infection markers—bacteria, pneumolysin, and inflammatory cellular infiltration—were classified according to patient age into 2 groups: young patients (YP) and old patients (OP). Age cutoff value of 50 years was selected based on receiver operating characteristic curve (ROC curve). Furthermore, for both age groups, in-hospital events, death, cerebrovascular stroke, reinfarction, lethal arrhythmias (ventricular tachycardia, ventricular fibrillation, asystole) and heart failure (Killip III and IV) were recorded. Death was recorded as cardiac and non-cardiac. Cardiac death was defined as death due to ventricular fibrillation, tachycardia, asystole, rupture ventricle, worsening heart failure, recurrent myocardial infarction, or cardiogenic shock. Non-cardiac death was defined as death due to cerebrovascular stroke, contrast-induced nephropathy, or other non-cardiac reasons. Reinfarction was diagnosed as rising of cardiac enzymes, CK, CK-MB, or cTnI above baseline level associated with chest pain and ST elevation/depression. Heart failure was defined as dyspnea because of worsening of left ventricular ejection fraction associated with rales at lung bases and auscultation of S3 heart sound in addition to impaired systolic function by echocardiography. All patients received optimal medical treatment for STEMI patients. The study was approved by the Ethical Committee of Faculty of Medicine in our University. All patients signed written consent for participation in the study, and the research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki.

**Statistical analysis**

Continuous variables were presented as mean ± SD in normal distributed variables and median (interquartile range, IQR) in non-normal distributed variables. Comparisons of means were done by using T test for normally distributed variables and Mann-Whitney U and Kruskal-Wallis tests for non-normal distributed variables. Categorical variables were presented as number (percentage). Comparisons between categorical variables were done by using chi-square with exact test. Multinomial logistic regression analysis using forward step-wise method was used to identify predictors of inhospital clinical events and predictors of bacteria, bacterial pneumolysin, and infiltration while predictors of STEMI in YP versus OP were identified by using binary
logistic regression analysis using forward stepwise method. ROC curve was used to identify optimal cutoff values for independent predictors (age and leukocytic count). All tests were performed by using SPSS package version 25 (IBM, New York, USA) except hazard ratio calculations which were calculated by using NCSS 2004/PASS 2002 (Utah, USA). Statistical tests were two-sided, and \( p < 0.05 \) was considered statistically significant.

Results

Clinical and laboratory results

STEMI patients treated with primary coronary intervention were 370 patients. Aspirates were obtained from 140 patients and were included in the study. Patients’ ages ranged from 22 to 90 years old. The majority of the patients, 81.4%, were between 41 and 70 years old. YP were 60 patients, 42.9%, while OP were 80 patients, 57.1%, Table 1. The median age of YP group was 45 (38–48) years, while the median age of OP group was 59 (55–65) years, \( p < 0.0001 \). Their clinical and catheterization data are summarized in Table 2. The 2 groups were comparable except for their ages, males, diabetes mellitus, dyslipidemia, positive family history, ectatic infarct artery, lesion length, intervention method (stenting), and stent length. YP group had significantly lower ages, diabetics, lesion length, stenting, and stent length and significantly higher males, dyslipidemia, positive family history, and ectatic vessels. Moreover, there was a trend for higher leukocytic count in the YP group.

The results of bacterial culture in both groups are shown in Table 3. Five types of bacteria were present in the aspirates of all examined patients, and most of them were *Klebsiella pneumoniae*. Positive samples for bacteria and pneumolysin were present in all studied aspirates. Of note, predictors of infection (bacteria, bacterial pneumolysin, and heavy infiltration) were (1) leukocytic count, (2) use of intravenous GP IIb/IIIa inhibitors, (3) left ventricular ejection fraction, (4) family history, (5) contrast-induced nephropathy, and (6) unsuccessful treatment of ventricular fibrillation were detected in 4 patients, 6.7%, in YP versus 2 patients, 2.5%, in OP, \( p = 0.13 \).

In-hospital clinical events

In-hospital clinical events were not significantly different between both groups, 7 patients, 11.7%, in YP versus 7 patients, 8.8%, in OP, \( p = 0.8 \). Contrast-induced nephropathy was encountered in YP group only, 2 (3.3%), while cerebrovascular stroke and heart failure were encountered in OP group only, 1 (1.3%) and 2 (2.5%), respectively. Refracture was seen in 1 patient of each group, 1.7% versus 1.3%, \( p = 0.99 \). Cardiac death due to unsuccessful treatment of ventricular fibrillation was detected in 4 patients, 6.7%, in YP versus 2 patients, 2.5%, in OP, \( p = 0.13 \).

Infection as a predictor

By multivariate analyses, independent predictors of STEMI in YP versus OP were (1) infection, bacteria, and pneumolysin [\( \text{Exp B} \ 20.72 \ (95\% \ CI \ 3.88–110.80), \ p < 0.001 \]; (2) hyperlipidemia [\( \text{Exp B} \ 12.38 \ (95\% \ CI \ 2.31–66.31), \ p = 0.003 \]; and (3) family history [\( \text{Exp B} \ 4.27 \ (95\% \ CI \ 1.58–11.50), \ p = 0.004 \]. The model could predict 79.8% correctly, and its –2log likelihood was 121.86 with goodness of fit Hosmer test \( p = 0.42 \).

Predictors of in-hospital clinical events were (1) ST-segment resolution (more than 50% reduction within 90 min after intervention), –2log likelihood ratio 151.93, \( p < 0.001 \; \text{and} \; (2) \) use of intravenous GP IIb/IIIa inhibitors, –2log likelihood ratio 139.58, \( p = 0.015 \); and (3) left ventricular ejection fraction, –2log likelihood ratio 114.28, \( p = 0.043 \). The model could predict 83.5% correctly. Of note, age groups, bacteria, bacterial pneumolysin, and leukocytic infiltration were not predictors of in-hospital clinical events.

Of note, predictors of infection (bacteria, bacterial pneumolysin, and heavy infiltration) were (1) leukocytic count, –2log likelihood ratio 215.54, \( p < 0.0001 \); and (2) age groups, –2log likelihood ratio 86.92, \( p = 0.027 \). The model could predict 90.7% correctly. By using ROC curve, leukocytic count produced high area under the curve, 0.97 (95% CI 0.95–1.0), \( p < 0.001 \), and age groups produced a significant area under the curve, 0.24 (95% CI 0.14–0.33), \( p = 0.001 \). The cutoff value of 50 years gave sensitivity of 29% and specificity of 62% for detection of bacteria and pneumolysin. Optimal cutoff value of leukocytic count was 12,250 cells/μL. It gave sensitivity

| Table 1 Age distribution in STEMI patients |
|-------------------------------------------|
| Age groups                  | Patients (n = 140) |
| From 20 to 30 years (%)       | 5 (3.6)           |
| From 31 to 40 years (%)       | 13 (9.3)          |
| From 41 to 50 years (%)       | 42 (30)           |
| From 51 to 60 years (%)       | 49 (35)           |
| From 61 to 70 years (%)       | 23 (16.4)         |
| From 71 to 80 years (%)       | 7 (5)             |
| From 81 to 90 years (%)       | 1 (0.7)           |

Data presented as number (%)
Table 2: Patients’ clinical and catheterization data in each group

|                      | YP (n = 60) | OP (n = 80) | p*  |
|----------------------|-------------|-------------|-----|
| Male (%)             | 52 (86.7)   | 55 (68.8)   | 0.016 |
| Age, years           | 45 (38–48)  | 59 (53–65)  | <0.0001 |
| Diabetes mellitus (%)| 12 (20)     | 31 (38.8)   | 0.026 |
| Hypertension (%)     | 9 (15)      | 19 (23.8)   | 0.3   |
| Smoking (%)          | 42 (70)     | 45 (56.3)   | 0.12  |
| Hyperlipidemia (%)   | 17 (28.3)   | 2 (2.5)     | <0.001 |
| Family history (%)   | 28 (46.7)   | 11 (13.8)   | <0.001 |
| Chest pain duration, h | 5 (3–7)    | 6 (3–9)     | 0.4   |
| Ejection fraction (%)| 50 (45.3–55.8) | 50 (47.0–45.8) | 0.4 |
| CK-max, IU/L         | 2200 (1345–3234) | 2168 (1464–3340) | 0.6   |
| CK-MB, μg/L          | 275 (201–393) | 259 (200–379) | 0.7   |
| WBCs, cell/μL        | 8600 (5625–13175) | 7580 (5805–10,200) | 0.09  |
| Door to balloon, min | 35 (30–45)  | 35 (30–43)  | 0.6   |
| Infarct related artery (%) | 0.6 |
| LAD                  | 37 (61.7)   | 44 (55)     |       |
| LCX                  | 6 (10)      | 7 (8.8)     |       |
| RCA                  | 17 (28.3)   | 29 (36.3)   |       |
| Diseased vessels/patients (%) | 2 (1–2) | 2 (1–3) | 0.28 |
| Reference vessel, mm | 3 (3–3.4)   | 3.25 (2.8–3.5) | 0.15  |
| Lesion length, mm    | 24.57 ± 7.91 | 27.56 ± 6.93 | 0.02  |
| Ectatic vessel (%)   | 9 (15)      | 3 (3.8)     | 0.03  |
| Thrombus grading (%) |            |             |       |
| 5                    | 35 (58.3)   | 52 (65)     |       |
| 4                    | 21 (35)     | 20 (25)     |       |
| 4                    | 4 (6.7)     | 8 (10)      |       |
| Preintervention TIMI flow (%) |     |             | 0.9  |
| ≤ 1                  | 55 (91.7)   | 74 (92.5)   |       |
| > 1                  | 5 (8.3)     | 6 (7.5)     |       |
| Intervention method (%) |         |             | 0.02  |
| Aspiration           | 3 (5)       | 2 (2.5)     |       |
| POBA                 | 7 (11.7)    | 1 (1.3)     |       |
| Stenting             | 50 (83.3)   | 77 (96.3)   |       |
| Stent type (%)       |            |             | 0.8   |
| DES                  | 13 (26)     | 18 (23.4)   |       |
| BMS                  | 37 (74)     | 59 (76.6)   |       |
| Stent length, mm     | 25 (20–33)  | 30 (24–38)  | 0.04  |
| Stent deployment pressure, atm | 14 (12–16) | 14 (12–16) | 0.6   |
| Postintervention TIMI flow (%) |     |             | 0.5  |
| 3                    | 57 (95)     | 75 (93.8)   |       |
| < 3                  | 3 (5)       | 5 (6.2)     |       |
| GPIIb/IIIa inhibitors (%) | 28 (46.7)  | 36 (45)     | 0.9   |
| ST-segment resolution (%) | 45 (75)    | 59 (73.8)   | 0.9   |

Data presented as number (%), median (IQR), or mean ± SD

BMS bare metal stent, DES drug-eluting stent, GP IIb/IIIa glycoprotein IIb/IIIa, LAD left anterior descending branch, LCX left circumflex branch, OP old patients group, POBA plain old balloon angioplasty, RCA right coronary artery, TIMI thrombolysis in myocardial infarction, YP young patients group

*YP versus OP
of 85.7% and specificity of 86.4% for detection of bacteria, and sensitivity of 87.5% and specificity of 91.9% for detection of a combination of bacteria and pneumolysin (shown in Figs. 1 and 2).

Discussion

The chief finding of this study is the presence of higher percentage of bacteria in the coronaries of young STEMI patients compared to old STEMI patients. The presence of bacteria, bacterial pneumolysin, and heavy leukocytic infiltration in coronary arteries of young STEMI patients denotes the involvement of bacteria in the process of myocardial infarction as a causative agent triggering infarction process and not responsible for in-hospital clinical events after coronary intervention. Both young-aged patients (≤ 50 years old) and a high leukocytic count (> 12250 cells/μl) are predictors of presence of bacteria in infarct-related artery.

Occurrence of myocardial infarction in very young patient, between 20 and 30 years, poses health and labor problems over a long time. Those patients are liable for heart failure, arrhythmias, recurrent angina, surgery, re-hospitalization, and even recurrent infarction [11, 27]. However, revascularization techniques such as percutaneous coronary and surgical interventions has improved mortality rate in young population [28]. Of note, coronary atherosclerosis is common in elderly patients. Its incidence reported in the Framingham Heart Study above 30 years old is < 20/1000 [28, 29]. While in our study, 3.6% of AMI patients are younger, < 30 years old. This suggests different geographic distribution and more severe form in our locality. Generally, the incidence of AMI in young population, < 50 years old, is low [2–6], and it is very low in population below 40 years old, 1.6% and 1.3%, as reported in Japan and Poland, respectively [2, 6]. It may be due to different reasons and/or risk factors. Traditional risk factors such as smoking, dyslipidemia, diabetes, and obesity are not always present in every young patient with myocardial infarction. In our study, some of young STEMI patients are free from traditional risk factors; consequently, other reasons or risk factors are considered. One of the reasons widely accepted is infection theory [13, 14, 22]. This is true in our study too, where bacteria are present in 11.3% of our patients and 85.6% of them is in young group. Moreover, multivariate analysis selects bacteria as an independent predictor. The great interest of AMI in young patients tries to explain mechanisms of infarction and to discover nontraditional risk factors [30, 31]. Spontaneous coronary artery dissection, plaque erosion, coronary microvascular dysfunction, myocarditis, coronary embolism, hypercoagulability, and coronary spasm are proved to cause myocardial infarction in this group of patients. Also, drug abuse causing coronary spasm is an important mechanism. Myocardial bridge and stress-induced cardiomyopathy known as Takotsubo cardiomyopathy can explain cases with acute coronary syndrome without atherosclerotic lesions [32]. Additionally, bacterial

| Table 3 | Types of bacteria in each group |
|-----------------|-----------------------------|-----------------------------|-----------------------------|
|                 | YP (n = 53/60)              | OP (n = 71/80)              | All patients (n = 124/140)  |
| **Klebsiella pneumoniae (%)** | 5 (9.4)                      | 1 (1.4)                     | 6 (4.8)                     |
| **Staphylococcus hominis (%)** | 3 (5.7)                      | 0 (0)                       | 3 (2.4)                     |
| **Staphylococcus pseudintermedius (%)** | 2 (3.8)                      | 1 (1.4)                     | 3 (2.4)                     |
| **Enterococcus bacterium (%)** | 1 (1.9)                      | 0 (0)                       | 1 (0.8)                     |
| **Pseudomonas stutzeri (%)** | 1 (1.9)                      | 0 (0)                       | 1 (0.8)                     |
| Total (%)       | 12 (22.6)                    | 2 (2.8)                     | 14 (11.3)                   |

Data presented as number (%)

OP old patients group, YP young patients group

| Table 4 | Results of bacteria, pneumolysin, infiltration, and hazard ratio of young versus old patients |
|-----------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
|                 | YP (n = 60)                     | OP (n = 80)                     | p                | HR (95% CI)                             | p * |
| Bacteria (%)    | 12 (22.6)                      | 2 (2.8)                        | 0.001            | 8.03 (1.83–51.49)                       | 0.002 |
| Bacteria or pneumolysin (%) | 13 (21.7)                      | 3 (3.8)                        | 0.002            | 5.78 (1.64–25.11)                       | 0.002 |
| Heavy inflammatory cell infiltration (%) | 8 (23.5)                      | 13 (28.9)                      | 0.6              | 0.81 (0.34–1.86)                       | 0.78  |
| Bacterial pneumolysin (%) | 1 (3.8)                        | 1 (2.9)                        | 1                | 1.31 (0.04–47.56)                       | 0.59  |
| Bacteria or heavy infiltration (%) | 18 (34)                       | 15 (21.1)                      | 0.12             | 1.61 (0.85–3.06)                       | 0.16  |
| Bacteria, heavy infiltration, or pneumolysin (%) | 19 (31.7)                      | 16 (20)                        | 0.2              | 1.58 (0.85–2.98)                       | 0.16  |

Data presented as number (%)

CI confidence interval, HR hazard ratio, OP old patients group, YP young patients group

*pSignificance of HR
Fig. 1 ROC curve for bacteria and pneumolysin showing age and leukocytic count predictors. The solid line represents leukocytic count. Its area under the curve is 0.97 (95% CI 0.95–1.0), \( p < 0.001 \). The thick dotted line represents age. Its area under the curve is 0.24 (95% CI 0.14–0.33), \( p = 0.001 \). The dotted line is the reference line.

Fig. 2 Cutoff value of leukocytic count for detection of bacteria in the aspirate of infarct related artery. It gives sensitivity of 85.7% and specificity of 86.4%.
infection can trigger coronary atherosclerosis and/or myocardial infarction which is evident in this study. YP have significantly higher males, hyperlipidemia, positive family history, and ectatic infarct-related artery while OP have higher diabetics. Similar results were reported by the AMI-Kyoto Multi-Center Risk Study Group in Japan except vessel ectasia [2] and more recently by Batra et al. [33].

In our study, 5 different types of bacteria are involved in the pathogenesis of AMI in 11.3% of patients. Higher incidence is reported by polymerase chain reaction for bacterial DNA [21, 22] supporting the role of infection in triggering acute coronary syndrome [13, 17]. Also, more diverse bacteria species are detected in atherosclerotic plaques [19, 24]. Their sources are usually different. Oral [34], periodontal [21], respiratory [15, 35–38], and gut microbiota [39–41] are involved in the pathogenesis of atherosclerosis and/or infarction. Although sieving theory, i.e., bacteremia followed by localization of bacteria at coronary artery, may theoretically explain presence of bacteria at coronary artery, absent [19] or lower concentrations [22] of bacteria in the systemic circulation exclude that theory. Bacteria and bacteria products as pneumolysin can cause direct cytotoxic effect, cellular pore-forming, activate cytokines, interleukin 6, tumor necrosis factor α, and activate neutrophil extracellular trap (NETosis) formation causing cellular damage [36]. The resultant degradation of plaque cap will eventually lead to plaque disruption and coronary thrombosis.

The in-hospital clinical outcomes in YP and OP are comparable. Neither age groups nor bacteria are predictors of short-term outcomes suggesting the role of bacteria as a triggering mechanism in the pathogenesis of myocardial infarction and no effect after primary coronary intervention. Of note, knowing the group with high percentage of bacteria, i.e., YP with elevated leukocytic count, does not only suggest nontraditional risk factors but also may guide preventive trials to select ischemic patients who may benefit from antimicrobial treatment which usually fails to give satisfactory secondary prevention results [42, 43].

**Study limitations**
The study has limitations. Use of thrombus aspiration catheters was operator-dependent decision so that not all incoming patients, 370 patients, were included in the study; however, calculating the power of our sample size, 60 and 80, with the 2 proportions, 22.6% and 2.8%, gives 91% which is good. The size of aspirate from the infarct-related artery was variable so laboratory tests could not be performed for all the patients equally. Detection of bacteria by polymerization chain reaction could not be performed because of logistic obstacles. Searching for the source of bacteria was not our scope. Detection of fungal and viral microbiome could not be performed. The study is a single center study though it is a tertiary center.

**Conclusions**
The aspirates of infarct-related artery contain bacteria which is present in higher concentration in young patients than old patients. Nontraditional risk factor for coronary artery disease is infection which can cause acute myocardial infarction especially in young patients and can be predicted by high leukocytic count in young patients. Further antimicrobial trials are needed focusing on this group of patient for secondary prophylaxis.

**Abbreviations**
AMI: Acute myocardial infarction; CK: Creatine kinase; CK-MB: Creatine kinase myocardial band; DNA: Deoxyribonucleic acid; GP IIb/IIIa inhibitors: Glycoprotein IIb/IIIa inhibitors; IQR: Interquartile range; OP: Old patients (> 50 years old) with STEMI; STEMI: ST-elevation myocardial infarction; cTnI: Cardiac troponin I; YP: Young patients (< 50 years old) with STEMI.

**Acknowledgements**
Not applicable.

**Ethics approval and consent to participate:**
Patients were included after written consent was signed by the patients. The study was supported by the Department of Research, Faculty of Medicine, Assiut University, Egypt. The Ethical Committee of Faculty of Medicine, Assiut University, gave approval number 17101037.

**Declarations**
The submitted article is an original article and has not been published before. The study was presented in-part in the 82 meeting of Japanese Circulation Society, Osaka as an oral presentation in 23.03.2018 (OE12-1).

**Author’s contributions**
MA has made the original hypothesis, performed statistical analysis and wrote the manuscript. The author read and approved the final manuscript.

**Funding**
The author of this manuscript declares not receiving any fund for this project except from the Department of Research, Faculty of Medicine, Assiut University.

**Availability of data and materials**
The manuscript data is available on request to the corresponding author.

**Consent for publication**
Not applicable.

**Competing interests**
The author declares that there are no competing interests.

**Received:** 10 October 2020 **Accepted:** 21 January 2021

**Published online:** 30 January 2021

**References**
1. Reed GW, Rossi JE, Cannon CP (2017) Acute myocardial infarction. Lancet 389:197–210
2. Shiraiishi J, Kohno Y, Yamaguchi S, Arihara M, Hadase M, Hyogo M et al (2005) Acute myocardial infarction in young Japanese adults clinical manifestations and in-hospital outcome. Circ J 69:1454–1458
3. Cui Y, Hao K, Takahashi J, Miyata S, Shindo T, Nishimiya K et al (2017) Age-specific trends in the incidence and in-hospital mortality of acute myocardial infarction over 30 years in Japan-report from the Miyagi AML Registry Study. Circ J 81:520–528
4. Wong CP, Loh SY, Loh KX, Ong PJ, Foo D, Ho HH (2012) Acute myocardial infarction: clinical features and outcomes in young adults in Singapore. World J Cardiol 4:206–210

5. Fang J, Alderman MH, Keenan NL, Ayala C (2010) Acute myocardial infarction hospitalization in the United States, 1979 to 2005. Am J Med 123: 259–266

6. Trzcinski P, Wozakowska-Kaplon B, Niezwiedza J, Gerlotka M, Hawthorne M, Lekston A et al (2016) Comparison of in-hospital and 12- and 36-month outcomes after acute coronary syndrome in men versus women <40 years (from the PL-ACS Registry). Am J Cardiol 118:1300–1305

7. Gale CP, Cattle BA, Baxter PD, Greenwood DC, Simms AD, Deanfield J et al (2013) Age-dependent inequalities in improvements in mortality or occur early after acute myocardial infarction in 476,242 patients in the Myocardial Ischaemia National Audit Project (MINAP) registry. Int J Cardiol 168:881–887

8. Reda A, Ashraf M, Soliman M, Ragy H, El Kersh A, Abdou W et al (2019) The pattern of risk-factor profile in Egyptian patients with acute coronary syndrome: phase II of the Egyptian cross-sectional CardioRisk project. CVJ Africa 3087–94

9. Schmidt M, Jacobsen JB, Lash TL, Barter HE, Sørensen HT (2012) 2012 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study. BMJ 344:e356. https://doi.org/10.1136/bmj.e356

10. McManus DD, Placentine SM, Lessard D, Gore JM, Yarzebski J, Spencer FA et al (2011) Thirty-year (1975 to 2005) trends in the incidence rates, clinical features, treatment practices, and short-term outcomes of patients <55 years of age hospitalized with an initial acute myocardial infarction. Am J Cardiol 108:477–482

11. O’Brien C, Valldottor L, Wasy JH, Strom JB, Secemsky EA, Wang Y et al (2017) Comparison of 30-day readmission rates after hospitalization for acute myocardial infarction in men versus women. Am J Cardiol 120:1070–1076

12. Kinosita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S et al (2018) Japanese Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb 25:846–984

13. Shah PK (2019) Inflammation, infection and atherosclerosis. Trends Cardiovasc Med 29:468–472. https://doi.org/10.1016/j.tcm.2019.01.004

14. Campbell LA, Rosenfeld ME (2015) Infection and atherosclerosis development. Arch Med Res 46:339–350

15. Mushler DM, Rueda AM, Kaka AS, Mapara SM (2007) The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 45:158–165

16. Arcari CM, Gaydos CA, Nieto FJ, Krauss M, Nelson KE (2005) Association between Chlamydia pneumoniae and acute myocardial infarction in young men in the United States military: the importance of timing of exposure measurement. Clin Infect Dis 40:1123–1130

17. Corrales-Medina VF, Madjid M, Mushler DM (2010) Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis 10:83–92

18. Tabata N, Sueta D, Akasaka T, Arima Y, Sakamoto K, Yamamoto E et al (2016) Helicobacter pylori seropositivity in patients with interleukin-1 polymorphisms is significantly associated with ST-segment elevation myocardial infarction. PLoS One 11:e0166240. https://doi.org/10.1371/journal.pone.0166240

19. Ott SJ, El Mokhtari NE, Murfetd M, Hellmig S, Freitag S, Rehman A et al (2015) Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease. Circulation 133:929–937

20. Ott SJ, El Mokhtari NE, Rehman A, Rosenstiel P, Hellmig S, Kühbacher T et al (2007) Fungal eDNA signatures in coronary atherosclerotic plaques. Environ Microbiol 9:3035–3045

21. Ohki T, Ijibashi Y, Kohno T, Yoshizawa A, Nishikubo S, Watanabe S et al (2012) Detection of periodontal bacteria in thrombus aspirates of patients with myocardial infarction by polymerase chain reaction. Am Heart J 163:164–167

22. Pesin T, Kehrulen V, Karjalainen PP, Ylitalo A, Alaistakinen JK, Niemi M et al (2013) Bacterial signatures in thrombus aspirates of patients with myocardial infarction. Circulation 127(1219-1228):e61–e66. https://doi.org/10.1161/CIRCULATIONAHA.112.01254

23. Pedicino D, Severino A, Ucci S, Bugli F, Flego D, Giglio AF et al (2017) Epicardial adipose tissue microbial colonization and inflammasome activation in acute coronary syndrome. Int J Cardiol 236:95–99

24. Katz JT, Shannon RP (2006) Bacteria and coronary atherosclerosis: more fingerprints but not smoking gun. Circulation 113:920–922

25. Farghaly AAA, Algowhary M, Abdelhman MZ, Hasan-Ali H, Dimitry SR (2019) Bacterial footprints in aspirate of infect-affected artery in ST-elevation myocardial infarction patients underwent primary percutaneous coronary intervention. Coron Artery Dis 30:494–498

26. Bainey KR, Armstrong PW (2016) Translational comparison of ST-segment elevation myocardial infarction guidelines: insights from the United States and Europe. J Am Coll Cardiol 67:216–229

27. Jing M, Gao F, Chen Q, de Carvalho LP, Sim LL, Koh TH et al (2016) Comparison of long-term mortality of patients aged ≤40 versus >40 years within acute myocardial infarction. Am J Cardiol 118:319–325

28. Tsiminetzky M, McManus DD, Gore JM, Yarzebski J, Coles A, Lessard D et al (2014) 30-year trends in patient characteristics, treatment practices, and long-term outcomes of adults aged 35 to 54 years hospitalized with acute myocardial infarction. Am J Cardiol 113:1137–1141

29. Kannel WB, Abbott RD (1984) Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham Study. N Engl J Med 311:1144–1147

30. Gulati R, Behfar A, Narula J, Kanwar A, Lerman A, Cooper L et al (2020) Acute myocardial infarction in young individuals. Mayo Clin Proc 95:136–156

31. Yang J, Biery DW, Singh A, Divakaran S, DeFilippis EM, Wu WY et al (2019) Risk factors and outcomes of very young adults who experience myocardial infarction: the Partners YOUNG-M Registry. Am J Med. https://doi.org/10.1016/j.amjmed.2019.10.029

32. Waterbury TM, Tarantini G, Vogel B, Mehran R, Gersh BJ, Gulati R (2019) Non-atherosclerotic causes of acute coronary syndromes. Nat Rev Cardioil 2019:1–26

33. Brown AO, Mann B, Gao G, Hankens JS, Humann J, Giardina J et al (2014) Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function. PLoS Pathog 10: e1004383. https://doi.org/10.1371/journal.ppat.1004383

34. Nel LG, Theron AJ, Durandt C, Tintinger GR, Pool R, Mitchell TJ et al (2016) Pneumolysin activates neutrophil extracellular trap formation. Clin Exp Immunol 184:358–367

35. Alhamdi Y, Neil DR, Abrams ST, Malik HA, Yahya R, Barrett-Jolley R et al (2015) Circulating pneumolysin is a potent inducer of cardiac injury during pneumococcal infection. PLoS Pathog 11:e1004836. https://doi.org/10.1371/journal.ppat.1004836

36. Corrales-Medina VF, Mushler DM, Wells GA, Chirinos JA, Chen L, Fine MU (2012) Cardiac complications in patients with community-acquired pneumonia incidence, timing, risk factors, and association with short-term mortality. Circulation 125:773–781

37. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X et al (2013) Intestinal microbial metabolism of phyllo直辖市aline and cardiovascular risk. N Engl J Med 368:1575–1584

38. Ascher S, Reinhart C (2018) The gut microbiota: an emerging risk factor for cardiovascular and cerebrovascular disease. Eur J Immunol 48:564–575

39. Emoto T, Yamashita T, Sasakii N, Horiya Y, Hayashi T, So A et al (2016) Analysis of gut microbiota in coronary artery disease patients: a possible link between gut microbiota and coronary artery disease. J Atheroscler Thromb 23:908–921

40. Anderson JL, Muhlestein JB, Carkiust Q, Allen A, Trehan S, Nielsen C et al (1999) Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: the Azithromycin in Coronary Artery Disease-Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 99:1540–1547

41. Song Z, Brassard P, Biophy JM (2008) A meta-analysis of antibiotic use for the secondary prevention of cardiovascular diseases. Can J Cardiol 24:391–395

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.